论文部分内容阅读
美国人类基因组科学公司（Ｈｕｍａｎ ＧｅｎｏｍｅＳｃｉｅｎｃｅｓ，ＨＧＳ）近日宣称其产品ＢｌｙＳ已获ＦＤＡ罕用药身份。ＢｌｙＳ是该公司进行临床研究的四种药物之一，其适应证为常见多样性免疫缺陷（ＣＶＩＤ）的治疗。ＢｌｙＳ的作用并不仅限于ＣＶＩＤ的治疗。Ｂｌｙ
Human Genome Sciences (HGS) recently announced that its product, BlyS, has received FDA’s regimen. BlyS is one of the company’s four drugs for clinical research, and its indications are the treatment of common diversity immunodeficiency (CVID). The role of BlyS is not limited to the treatment of CVIDs. Bly